Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Study protocol

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen

Emily J Henderson1*, Stephen R Lord2, Jacqueline CT Close23, Andrew D Lawrence4, Alan Whone56 and Yoav Ben-Shlomo1

Author Affiliations

1 Department of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, BS8 2PS Bristol, UK

2 Neuroscience Research Australia, University of New South Wales, Sydney, Australia

3 Prince of Wales Clinical School, Department of Geriatric Medicine, Sydney, NSW, Australia

4 School of Psychology, Cardiff University, Cardiff, UK

5 Department of Neurology, Institute of Clinical Neurosciences, University of Bristol, Bristol, UK

6 North Bristol NHS Trust, Bristol, UK

For all author emails, please log on.

BMC Neurology 2013, 13:188  doi:10.1186/1471-2377-13-188


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2377/13/188


Received:4 November 2013
Accepted:11 November 2013
Published:3 December 2013

© 2013 Henderson et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

Background

Gait impairment is common in people with Parkinson’s disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson’s disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson’s disease.

Methods/design

This is a single centre, double-blind, randomised placebo-controlled trial in 130 people with Hoehn and Yahr stage 2–3 idiopathic Parkinson’s disease who have fallen in the past year. Participants will be randomised to two groups, receiving either rivastigmine capsules or identical placebo capsules for 8 months. Assessment will be undertaken at baseline and at the end of medication prescription (i.e. 8 months) with participants remaining enrolled in the trial for a further 4 months to monitor for falls and adverse events. The primary outcome is step time variability, assessed with and without the addition of concurrent cognitive tasks. Secondary outcomes will include other gait parameters, sensorimotor and balance performances, cognitive indices, falls and fall related injury, fear of falling, Parkinson’s symptoms and data pertaining to possible harms.

Discussion

This randomised controlled trial will examine the effect of cholinesterase inhibitor therapy on gait, balance and falls in Parkinson’s disease. If effective, it would offer a new therapeutic option to ameliorating gait and cognitive deficits in a population at high risk of falls.

Trial registration

ISRCTN19880883, UTN U1111-1124-0244.

Keywords:
Randomised control trial; Parkinson’s disease; Accidental Falls; Freezing of gait; Intervention; Gait analysis; Acetylcholinesterase; Cognitive; Attention; Dual-tasking

Background

Falls are a common and devastating complication of Parkinson’s disease (PD). Whilst tremor, akinesia and rigidity are early motor manifestations, postural instability tends to emerge as the disease progresses. Postural instability, coupled with gait dysfunction, is a major determinant of disability [1] with mobility and walking limitation cited by patients as the worst aspect of the disease [2]. Falls are a cause of significant morbidity. The consequences include fractures and injuries [3], fear of falling [4], nursing home and hospital admission [5] carer strain [6] and increased mortality [7]. Gait impairment, postural instability and falls are common complications of PD and may have a greater impact on quality of life than motor complications and dyskinesia [8]. There is currently a lack of pharmacological options of proven efficacy for addressing falls, postural instability, freezing of gait and festination in this high risk population.

The burden of disease complications will inevitably increase as the number of people with Parkinson’s disease in the most populous nations is expected to double from 2005 to 2030 [9]. A meta-analysis of prospective studies exploring falls in people with Parkinson’s disease demonstrated that 46% of individuals fall at least once over a period of three months [10]. Twenty years from diagnosis, 87% of people with Parkinson’s disease in the Sydney cohort had fallen with 35% sustaining a fracture [11]. The peak risk of falls corresponds with Hoehn and Yahr stage three [12] where people are still mobile but have reduced stability.

Despite increasing recognition of the non-motor features of the disease, the mainstay of pharmacological therapy remains dopaminergic medications. However, disorders of gait and balance in PD are not generally ameliorated by typical dopaminergic medication. During the maintenance and early complications phase of the disease, gait disturbances and end of dose freezing, typically respond to dopaminergic agents. As the condition progresses with associated motor complications, response to treatment becomes less predictable and freezing may develop in the “on” stage [13]. As Parkinson’s disease advances, “off” freezing becomes unpredictable despite optimisation of medical therapy and levodopa-induced dyskinesias and ‘on’ freezing further contribute to the risk of an individual falling.

Characterisation of the cholinergic neurochemical deficit that is thought to underlie gait disorders and postural instability has aided the search for potential therapeutic targets. The predominantly cholinergic pedunculopontine nucleus (PPN) provides input into the basal ganglia and cortex and undergoes degeneration in PD. The extent of degeneration is correlated with the degree of gait dysfunction [14]. Cortical and thalamic cholinergic loss, representing projections from the nucleus basalis of Meynert (nbM) and the PPN respectively, is significantly greater in people with PD and a history of falls compared to both those without falls and non-PD controls [15]. Similarly, the degree of cholinergic neuronal loss is negatively correlated with the Hoehn and Yahr score, which is driven by the progressive emergence of axial impairment [16].

Outside of a potential role in gait dysfunction, cholinergic loss manifests as an alteration in attention and cognition [17]. Furthermore mild cognitive impairment (MCI) is highly prevalent in people with PD and increases with age, duration and severity of PD and affects a range of cognitive domains [18]. The nbM is the main source of cholinergic projections to the cerebral cortex and degenerates in PD [19]. Greater cholinergic neuronal loss in the nbM is seen in people with Parkinson’s disease dementia (PDD) than in PD [20], and neuroimaging evidence of this cholinergic dysfunction is present early in the disease course [21].

The observed deficit in cholinergic function in Parkinson’s disease thus accounts, at least to some degree, for the dysfunction seen in both cognitive and gait domains. Historically, gait has been regarded as demanding little or no cognitive resources. The dual-task technique provides a means to examine the extent to which different activities demand attentional capacity, i.e. draw on common central processing resources. In dual-task experiments, a decrement in performance occurring when two tasks are performed simultaneously (relative to baseline performance on each single task) indicates that both tasks demand attention [22].

Dual-task paradigms have revealed important insights into the relationship between gait and cognition. Dual-task conditions augment gait impairments seen during normal walking in PD such as reduction in gait speed, stride length and increased stride-to-stride variability [23]. Furthermore, in PD, a ‘posture second’ strategy seems to be adopted whereby individuals are unable to appropriately prioritise the safety of their walking above other cognitive demands [24].

Despite evidence that cholinergic loss may influence both gait and cognitive changes, few have studied the effect of cholinergic augmentation on gait, balance and falls. A small trial of six individuals with Alzheimer’s disease (AD) versus eight controls with MCI examined the effect of a 4 month period of treatment with the acetylcholineseterase inhibitor donepezil. This demonstrated that both gait velocity and variability improved under single and dual-task conditions at follow-up [25]. Two further studies showed an improvement in stride time [26] and a reduction in falls with treatment [25,27]. A further RCT is currently underway examining these effects on a larger cohort of individuals with MCI [28]. In Parkinson’s disease, a small cross over trial of donepezil showed a reduction in fall rate, though this was driven primarily by reductions in only those with a history of very frequent falls [27].

The aim of this randomised controlled trial is to examine the effect of cholinesterase inhibitor therapy on gait and balance and fall risk in people with Parkinson’s disease with a history of one or more falls in the past year.

Methods

Design

A placebo-controlled double blind, randomised clinical trial (RCT) using a parallel arm design (Figure 1).

thumbnailFigure 1. Trial flow diagram.

Participants and setting

Participants will be eligible if they meet the following inclusion criteria; a) have moderate Parkinson’s disease (Hoehn and Yahr stage 2–3), b) have fallen in the last year, c) are able to walk without aids for the distance of the walking protocol (approximately 18 metres), d) have been stable on anti-Parkinsonian medication for 2 weeks prior to enrolment and e) are able to give informed consent. Potential participants will be excluded if they: a) have any other cause contributing to their Parkinsonian features (vascular disease, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), normal pressure hydrocephalus), b) have a known diagnosis of dementia, c) have other neurological, visual or orthopaedic problems that significantly interfere with balance or gait, d) have had previous or current treatment with a cholinesterase inhibitor or an absolute contraindication to cholinesterase inhibitor therapy, e) are unable to attend or comply with treatment or follow-up scheduling and f) are non-English speaking as cognitive tests will be performed in English.

Ethical approval was granted from the South West Research Ethics Committee on 28th September 2011 and the Medicines and Healthcare Regulatory Agency (MHRA) on 18th June 2012.

Participants will be identified from centres in the South West of England and South East Wales by Parkinson’s specialist clinicians, through the DeNDRoN (Dementias and Neurodegenerative Diseases Research Network) and via advertising through the Parkinson’s Disease-UK charity. Participants will also be identified through National Health Service (NHS) Trusts acting as Participant Identification Centres (PICs) predominantly in neighbouring regions of South West England. The trial is a single site study based in a NHS Trust hospital.

Participants will be sent or given an information pack that provides further details about the study and asked to return a reply slip indicating their interest in taking part. Interested participants will be screened by telephone and offered an appointment if they meet the inclusion criteria. Written informed consent will be obtained from all participants.

Randomisation and blinding

After confirming eligibility and obtaining informed consent, participants will be randomised to one of two treatment arms. Both the assessors and participants will be blinded to the treatment allocation throughout the trial. Unblinding will occur once all assessments are complete and the database has been locked at the end of the trial. The randomisation sequence will be generated by Bristol Randomised Trials Collaboration (BRTC) clinical trials unit. We will use a minimisation algorithm with a random element to ensure that the two trial arms are similar on three key variables: age, cognitive impairment (using the Montreal Cognitive Assessment (MOCA)) and number of falls sustained in the past year. The list will be generated by a web based program which then issues a treatment pack number that is matched to a drug package held in the pharmacy, thereby ensuring concealment of allocation.

Assessment procedures

Participants will visit the hospital on two occasions to undergo assessment, at baseline and after 32 weeks of treatment. The baseline visit will involve checking eligibility against the inclusion and exclusion criteria and administering questionnaires relating to sociodemographic and general health measures. Assessment of physical and cognitive function, a physical examination and recording of an electrocardiogram will also be undertaken. If eligible and willing to participate, informed consent will be obtained and participants will be randomised at this stage.

At both visits, assessments will include cognitive tests, analysis of fall risk, and gait and balance testing. Falls and adverse event data will be ascertained by monthly follow-up phone calls. Visit 2 will additionally involve ascertainment of osteoporosis risk factors and measurement of frailty status to reduce the assessment burden for visit 1. Table 1 illustrates the assessments performed at each visit and whether these are primary or secondary outcome measures.

Table 1. Assessments at baseline (BA) and at follow-up (FUA) indicating primary (1°) and secondary (2°) outcomes (O)

Intervention

Participants will receive either rivastigmine or an identically matched placebo in treatment packs at visit one. They will be instructed to take one tablet twice a day. All participants will up-titrate the dose every four weeks (1.5 mg, 3 mg, 4.5 mg and 6 mg rivastigmine or matched placebo) over a 16 week period. This slower four week up-titration schedule has been adopted in other clinical trials on the basis of optimising tolerability [45,46]. The up-titration phase will be followed by a 16 week maintenance dose period after which time the medication will be stopped, yielding a total treatment period of 32 weeks (Figure 2). In the event of unacceptable side effects occurring, participants will be instructed to down-titrate to the last tolerated dose or stop the medication according to clinical judgement.

thumbnailFigure 2. Schedule of assessment visits, medication titration and monitoring of adverse events and falls.

Primary outcome measure - step time variability

The primary outcome measure will be step time variability assessed in three walking conditions: normal walking, (b) walking while performing a verbal fluency task and (c) walking while performing a verbal fluency switching task. Variability will be calculated according to current recommendations [47] as both the standard deviation (SD) and the coefficient of variation (CoV) (SD/mean x 100%). The SD for the three walking conditions will be reported as the primary outcome measure, though we hypothesise a priori that any observed differences will be magnified with increasing cognitive demands. Each condition is repeated three times for a total of nine walks. Gait will be assessed with an accelerometer, housed in a small, lightweight (5 g) container attached to the participant’s waist with an elasticated belt (Dynaport Hybrid system, McRoberts). Participants will be tested whilst in the ‘on’ medication state and will be instructed to walk at self-selected speeds over a 22 m obstacle-free level corridor, wearing their normal footwear and clothing. During the dual-task conditions, participants will not be given instructions as to which task to prioritise. The verbal fluency task is based on the controlled oral word association test (COWAT) whereby participants are asked to name as many words as they can beginning with a given letter of the alphabet. The switching dual-task is a more challenging version of COWAT. Participants are instructed to switch alternately between words beginning with two different letters of the alphabet. Letters are selected based on their frequency in the English dictionary and thus perceived difficulty. The three walking conditions will be randomly ordered to minimise practice effects. In the event of a failure on either the cognitive task or walking the participant will be prompted to continue. Cognitive task performance will be recorded using a lightweight non-obstructive dictaphone worn by participants.

Secondary outcome measures

Additional gait measures

In addition to step time variability, we will assess the effects of the intervention on a number of other gait parameters: harmonic ratios, velocity (m/s), cadence (steps/min), step length (cm), stance time (sec), stance time variability, double limb support (% of gait cycle) and walk ratio (see Appendix 1 for more details).

Freezing of gait will be assessed by asking participants to stand from a chair, walk between two chairs placed 50 cm apart, turn 360° to the right, 540° to the left and then walk back the same way and return to the chair. The walks will be videotaped to classify the type and duration of any freezing episodes. Freezing of gait will be also measured using the FOG questionnaire [40].

Controlled leaning balance

Controlled leaning balance will be assessed with the coordinated stability test which requires participants to accurately adjust their position in a steady and coordinated manner when their centre of mass is near the limits of their base of support [41].

Fall risk indices

Fall risk will be assessed with two validated mea-sures - the short-form Physiological Profile Assessment (PPA) [42] and the Parkinson’s disease fall risk index (PDFRI) [48].

The PPA consists of five measures of sensorimotor performance including (1) visual contrast sensitivity, (2) proprioception, (3) quadriceps muscle strength, (4) hand reaction time and (5) postural sway. Visual contrast sensitivity is assessed using the Melbourne Edge Test. The chart has 20 circular patches containing edges with reducing contrast with variable orientation as the identifying feature. Correct identification of the orientation of the edge on the patches provides a measure of contrast sensitivity in decibel units, where 1 dB = 10 log10 contrast. Proprioception is measured using a lower-limb matching test, where difference in matching the great toes in degrees is recorded using a vertical clear acrylic sheet inscribed with a protractor and placed between the legs. Quadriceps muscle strength (isometric) in kilograms is examined in the dominant leg using a spring gauge while participants are seated with the hip and the knee joint at 90° of flexion. Simple reaction time in milliseconds is assessed using a light as a stimuli and a finger-depression of a switch as the response. Postural sway (total sway path in millimeters) is assessed using a swaymeter that measures the displacement of the body at waist level while participants stand for 30 seconds on a foam rubber mat with eyes open. The five PPA components are weighted to compute a composite PPA fall risk score which has been shown to prospectively discriminate between older fallers and non-fallers with an accuracy up to 75% [42].

The complementary PDFRI is calculated from an algorithm comprising measures of gait freezing, abnormal posture, executive functioning, coordinated stability and lower limb weakness. In a study of 113 participants with PD this index discriminated between fallers and non-fallers with a sensitivity of 77% and a specificity of 82% [48].

Cognitive assessment, mood and quality of life

Cognition will be measured using the Montreal Cognitive Assessment (MOCA) [49], Cognitive Failures Questionnaire (CFQ) [36], Test Your Memory (TYM) tool [37], Frontal Assessment Battery (FAB [38]), and verbal fluency performance assessed whilst seated using the COWAT (described above). Fear of falling will be quantified using the short version of the Iconographical Falls Efficacy Scale (Icon-FES) [50], mood will be assessed with the 15 item Geriatric Depression Score [39] and quality of life will be assessed using EQ-5D-5L [34].

Parkinson’s disease symptoms

Parkinson’s disease symptoms and stage will be assessed using the new Unified Parkinson’s Disease Rating Scale [44] (UPDRS) which incorporates a patient completed non motor and motor aspects of daily living, a clinician completed assessment of motor complications and results of a motor examination.

Falls

Falls and resultant injuries will be assessed as the number and rate of falls, proportion of fallers in each group, injury and injury related healthcare use. A fall will be defined as “an unexpected event in which participants come to rest on the ground, floor, or lower level” [51]. Falls will be recorded with falls diaries. All participants will receive monthly calendars on entry to the study which are returned in pre-paid envelopes to the research personnel. The calendars record the number of falls in a grid calendar and separate sheets record the circumstances for each fall. Participants will also be routinely telephoned monthly to verify any falls data and be screened for other adverse events.

Safety

Participants will be asked to notify the research team by phone if they experience any adverse events. Additionally, all participants will be screened during the monthly phone calls for adverse events using an open ended, non-leading question. Serious adverse events will be defined as events that result in death, hospitalisation (except for a pre-existing condition that had not worsened), significant disability or incapacity.

Potential worsening of extrapyramidal symptoms has been previously cited as a concern when prescribing cholinesterase inhibitors in Parkinson’s disease. A large multicentre placebo controlled trial of 541 people with mild to moderate dementia related to Parkinson’s disease demonstrated improvement in cognitive scores [45]. Worsening of tremor is a recognised side effect of rivastigmine but was only sufficiently severe to cause withdrawal of 1.7% of patients treated in the aforementioned trial. Monthly phone calls and access to the trial team should facilitate rapid reporting of such symptoms and appropriate down titration or cessation of the drug where clinically appropriate.

Adherence will be measured with a pill count of returned medications. This will be compared with the participant’s reported adherence on the basis of information ascertained during the follow-up phone calls and at the second face-to-face assessment visit.

Sample size

As there are no data on the effect of rivastigmine treatment on step time variability, our sample size calculation has been estimated by extrapolating from related studies. For example, it has been found that treatment with donepezil resulted in a reduction in gait variability (22.3 to 11.3% CoV) for AD patients in a non-randomized trial [25].

Pragmatically, we estimate that we can recruit 130 eligible participants for the study over a 12 month period. Assuming a 30% drop out (based on a previous RCT [45]) this would result in approximately 90 patients (45 per arm) with trial data. This will enable us to detect a treatment effect difference of 0.6 standardised (z-score) units for our primary outcome measure (step time variability) with 80% power and at a two-sided 5% significance level. This sample size is similar to a study currently being undertaken in non-PD patients with mild cognitive impairment, i.e. 140 participants [28]. The use of a dual-task paradigm, as a cognitive stressor, may produce a more sensitive measure of any treatment benefit.

The clinical impact of such a group difference in gait variability can be estimated from a study by Maki [52]. In a cohort of 75 elderly volunteers without PD, a 0.6 standardised difference in stride velocity and stride length was associated with a 1.65 and 1.50 increased odds ratio of falling respectively, which would translate into clinically important benefits. We have assumed that these results will generalize to PD populations, and also manifest in step time variability, possibly a better predictor of fall risk in this population [53].

Statistical analysis

Simple descriptive statistical analyses will initially be undertaken on all outcomes measures. For continuous measures (e.g. step time, step length and variability) the mean, SDs and distributions will be examined. Where measures are skewed, transformation will be undertaken. Outcome data on falls will be analysed by: (i) number of falls (count), (ii) non-fallers, low frequency of falls and frequent fallers (categorical ordinal variable), (iii) fall rate per person month (rate) and (iv) proportion of fallers in each group. Injury data will be summarized as (i) peripheral fracture rate per person-year of follow-up, (ii) number of peripheral fractures, (iii) number of people sustaining peripheral fractures, and (iv) number of people sustaining multiple events. For these variables, frequency counts (e.g. categorical variables) or Kaplan Meier plots for survival time variables will be analysed. Other binary or categorical measures (such as adverse event data) will be examined by simple frequency counts and contingency tables with Chi2 tests of association.

The main analyses will be performed using the intention to treat principle. For the primary outcome measure (step variability), we will use multivariable linear regression models and adjust for baseline or other covariates to increase precision. Hence we will compare group differences at 32 weeks in the gait variability parameters conditional on baseline parameters. For the secondary outcomes we can use ordinal logistic regression (e.g. for frequency of falls as an ordinal variable), Cox’s proportional hazard model for time to first fall and negative binomial regression to compare fall rates between groups. The last method accounts for falls clustering within participants, and has been recommended for falls data analysis [54]. The baseline covariates will be adjusted for as appropriate.

For participants who fail to complete the follow-up, sensitivity analyses will be undertaken, using multiple imputation methods. There are no planned interim analyses and no formal adjustments will be used for multiple testing though we will be cautious in our interpretation of the secondary outcomes (especially when the p-value is in the range of between 0.01 and 0.05) given the possibility of type I errors.

Discussion

Falls and the consequences thereof are devastating to people with Parkinson’s disease. This trial will provide new insight into the effect of cholinesterase inhibitors on gait, balance and fall risk in this vulnerable group. It will establish and further validate falls prediction algorithms and delineate the interaction of multiple key risk factors that contribute to the high rate of falls that occur in this vulnerable population. Rivastigmine could potentially represent a safe and cost effective therapeutic approach to treating gait and balance dysfunction in Parkinson’s disease utilising an already established pharmacological agent. Hence, this may offer an effective, acceptable intervention in an area of Parkinson’s disease where there are currently unmet symptom needs and little in the way of evidence based therapeutic strategies.

Appendix 1

The gait parameter definitions are described in Table 2. Step time variability is the primary outcome measure. The effect of the intervention will be measured on the other gait parameters listed.

Table 2. Gait parameter definitions used in the ReSPonD trial

Competing interests

SL: The Physiological Profile Assessment (NeuRA FallScreen) is commercially available through Neuroscience Research Australia.

No other competing interests declared.

Authors’ contributions

AW and EH conceived the idea for the study. AW, YBS, EH, JC, SL and AL participated in the design of the study. EH drafted this manuscript for submission. All authors read and approved the final manuscript.

Acknowledgements

The trial has been funded by a Parkinson’s UK career development award (F1003) awarded to EH. The active and placebo investigation medicinal product is supplied free of charge by Novartis who provided feedback regarding the dosing of the trial medication but had no other input into the design or implementation of the study and did not participate in preparing this manuscript for publication. The University of Bristol acts as the research sponsor.

References

  1. Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ: Determinants of disability and quality of life in mild to moderate Parkinson disease.

    Neurology 2008, 70:2241-2247. PubMed Abstract | Publisher Full Text OpenURL

  2. Schenkman M, Cutson TM, Zhu CW, Whetten-Goldstein K: A longitudinal evaluation of patients’ perceptions of Parkinson’s disease.

    Gerontologist 2002, 42:790-798. PubMed Abstract | Publisher Full Text OpenURL

  3. Genever RW, Downes TW, Medcalf P: Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study.

    Age Ageing 2005, 34:21-24. PubMed Abstract | Publisher Full Text OpenURL

  4. Mak MKY, Pang MYC: Fear of falling is independently associated with recurrent falls in patients with Parkinson’s disease: a 1-year prospective study.

    J Neurol 2009, 256:1689-1695. PubMed Abstract | Publisher Full Text OpenURL

  5. Hely MA, Morris JGL, Traficante R, Reid WGJ, Sullivan DJO, Williamson PM: The Sydney multicentre study of Parkinson’ s disease: progression and mortality at 10 years.

    J Neurol 1999, 67:300-307. OpenURL

  6. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M: Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability.

    Parkinsonism Relat Disord 2006, 12:35-41. PubMed Abstract | Publisher Full Text OpenURL

  7. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, Poewe W, Litvan I: Progression of falls in postmortem-confirmed parkinsonian disorders.

    Mov Disord 1999, 14:947-950. PubMed Abstract | Publisher Full Text OpenURL

  8. Schrag A, Ben-Shlomo Y, Quinn N: How common are complications of Parkinson’s disease?

    J Neurol 2002, 249:419-423. PubMed Abstract | Publisher Full Text OpenURL

  9. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

    Neurology 2007, 68:384-386. PubMed Abstract | Publisher Full Text OpenURL

  10. Pickering RM, Grimbergen YAM, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR: A meta-analysis of six prospective studies of falling in Parkinson’s disease.

    Mov Disord 2007, 22:1892-1900. PubMed Abstract | Publisher Full Text OpenURL

  11. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL: The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years.

    Mov Disord 2008, 23:837-844. PubMed Abstract | Publisher Full Text OpenURL

  12. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N: Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors.

    J Neurol 2005, 252:1310-1315. PubMed Abstract | Publisher Full Text OpenURL

  13. López IC, Ruiz PJG, Del Pozo SVF, Bernardos VS: Motor complications in Parkinson’s disease: ten year follow-up study.

    Mov Disord 2010, 25:2735-2739. PubMed Abstract | Publisher Full Text OpenURL

  14. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker H-P, Hunot S, Hartmann A, Lehericy S, Hirsch EC, Francois C: Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease.

    J Clin Invest 2010, 120:2745-2754. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  15. Bohnen NI, Muller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL: History of falls in Parkinson disease is associated with reduced cholinergic activity.

    Neurology 2009, 73(20):1670-1676. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  16. Rinne JO, Ma SY, Lee MS, Collan Y, Röyttä M: Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients.

    Parkinsonism Relat Disord 2008, 14:553-557. PubMed Abstract | Publisher Full Text OpenURL

  17. Lawrence AD, Sahakian BJ: Alzheimer disease, attention, and the cholinergic system.

    Alzheimer Dis Assoc Disord 1995, 9(2):37-49. PubMed Abstract OpenURL

  18. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M: Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines.

    Mov Disord 2012, 27:349-356. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  19. Nakano I, Hirano A: Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease.

    Ann Neurol 2004, 15(5):415-418. OpenURL

  20. Jellinger K: The morphological basis of mental dysfunction in Parkinson’s disease.

    J Neurol Sci 2006, 248:167-172. PubMed Abstract | Publisher Full Text OpenURL

  21. Hilker R, Thomas A, Klein J: Dementia in Parkinson disease functional imaging of cholinergic and dopaminergic pathways.

    Neurology 2005, 65:1716-1722. PubMed Abstract | Publisher Full Text OpenURL

  22. Kahneman D: Attention and effort, Volume 88. Englewood Cliffs, NJ: Prentice-Hall; 1973. OpenURL

  23. Kelly V, Eusterbrock A, Shumway-Cook A: A review of dual-task walking deficits in people with Parkinson’s disease: motor and cognitive contributions, mechanisms, and clinical implications.

    Park Dis 2012, 2012:918719. OpenURL

  24. Bloem BR, Grimbergen YAM, van Dijk JG, Munneke M: The “posture second” strategy: a review of wrong priorities in Parkinson’s disease.

    J Neurol Sci 2006, 248:196-204. PubMed Abstract | Publisher Full Text OpenURL

  25. Montero-Odasso M: Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls.

    J Am Geriatr Soc 2009, 57:359-360. PubMed Abstract | Publisher Full Text OpenURL

  26. Assal F, Allali G: Galantamine improves gait performance in patients with Alzheimer’s disease.

    J Am Geriatr Soc 2008, 56:946-947. PubMed Abstract | Publisher Full Text OpenURL

  27. Chung KA, Lobb BM, Nutt JG, Horak FB: Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.

    Neurology 2010, 75:1263-1269. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  28. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M: Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.

    BMC Neurol 2009, 9:42. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  29. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E: FRAX and the assessment of fracture probability in men and women from the UK.

    Osteoporos Int 2008, 19:385-397. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  30. Hippisley-Cox J, Coupland C: Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study.

    BMJ 2012, 344:e3427. PubMed Abstract | Publisher Full Text OpenURL

  31. Rockwood K, Song X, Macknight C, Bergman H, Hogan DB, Mcdowell I, Mitnitski A: A global clinical measure of fitness and frailty in elderly people.

    Can Med J 2005, 173:489-495. Publisher Full Text OpenURL

  32. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Frailty in older adults: evidence for a phenotype.

    J Gerontol A Biol Sci Med Sci 2001, 56:M146-M157. PubMed Abstract | Publisher Full Text OpenURL

  33. Washburn R, Smith K, Jette A, Janney C: The Physical Activity Scale for the Elderly (PASE): development and evaluation.

    J Clin Epidemiol 1993, 46:153-162. PubMed Abstract | Publisher Full Text OpenURL

  34. Schrag A, Selai C: The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson’s disease.

    J Neurol 2000, 69:67-73. OpenURL

  35. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY: A recommended scale for cognitive screening in clinical trials of Parkinson’s disease.

    Mov Disord 2010, 25:2501-2507. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  36. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR: The Cognitive Failures Questionnaire (CFQ) and its correlates.

    Br J Clin Psychol 1982, 21:1-16. PubMed Abstract | Publisher Full Text OpenURL

  37. Brown J, Pengas G, Dawson K: Self administered cognitive screening test (TYM) for detection of Alzheimer’s disease: cross sectional study.

    BMJ 2009, 338:b2030. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  38. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB A frontal assessment battery at bedside.

    Neurology 2000, 55(11):1621-1626. PubMed Abstract | Publisher Full Text OpenURL

  39. Meara J, Mitchelmore E, Hobson P: GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community.

    Age Ageing 1999, 28:35-38. PubMed Abstract | Publisher Full Text OpenURL

  40. Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T, Giladi N: Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson’s disease and their carers.

    Gait Posture 2009, 30:459-463. PubMed Abstract | Publisher Full Text OpenURL

  41. Lord S, Ward J, Williams P: Exercise effect on dynamic stability in older women: a randomized controlled trial.

    Arch Phys Med Rehabil 1996, 77(March):232-236. PubMed Abstract | Publisher Full Text OpenURL

  42. Lord S, Menz H, Tiedemann A: A physiological profile approach to falls risk assessment and prevention.

    Phys Ther 2003, 83:237-252. PubMed Abstract | Publisher Full Text OpenURL

  43. Paul SS, Canning CG, Sherrington C, Lord SR, Close JCT, Fung VSC: Three simple clinical tests to accurately predict falls in people with Parkinson’s disease.

    Mov Disord 2013, 28:655-662. PubMed Abstract | Publisher Full Text OpenURL

  44. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

    Mov Disord 2008, 23:2129-2170. PubMed Abstract | Publisher Full Text OpenURL

  45. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin SLR: Rivastigmine for dementia associated with Parkinson’s disease.

    N Engl J Med 2004, 351:2509-2518. PubMed Abstract | Publisher Full Text OpenURL

  46. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo J-M, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R: Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study.

    Lancet Neurol 2007, 6:501-512. PubMed Abstract | Publisher Full Text OpenURL

  47. Hausdorff JM: Gait variability : methods, modeling and meaning.

    J Neuroeng Rehabil 2005, 2:19. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  48. Latt MD, Lord SR, Morris JGL, Fung VSC: Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease.

    Mov Disord 2009, 24:1280-1289. PubMed Abstract | Publisher Full Text OpenURL

  49. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ: The MoCA: well-suited screen for cognitive impairment in Parkinson disease.

    Neurology 2010, 75:1717-1725. PubMed Abstract | Publisher Full Text OpenURL

  50. Delbaere K, Smith ST, Lord SR: Development and initial validation of the iconographical falls efficacy scale.

    J Gerontol A Biol Sci Med Sci 2011, 66:674-680. PubMed Abstract | Publisher Full Text OpenURL

  51. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C: Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus.

    J Am Geriatr Soc 2005, 53:1618-1622. PubMed Abstract | Publisher Full Text OpenURL

  52. Maki BE: Gait changes in older adults: predictors of falls or indicators of fear.

    J Am Geriatr Soc 1997, 45:313-320. PubMed Abstract OpenURL

  53. Hausdorff JM, Balash J, Giladi N: Effects of cognitive challenge on Gait variability in patients with Parkinson’s disease.

    J Geriatr Psychiatry Neurol 2003, 16:53-58. PubMed Abstract | Publisher Full Text OpenURL

  54. Robertson MC, Campbell AJ, Herbison P: Statistical analysis of efficacy in falls prevention trials.

    J Gerontol A Biol Sci Med Sci 2005, 60:530-534. PubMed Abstract | Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/13/188/prepub